Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Involvement of complement components in renal disease

R J Johnson1

  • 1Baxter Healthcare Corporation, Corporate Research and Technical Services, Round Lake, Illinois 60073, USA.

Current Opinion in Nephrology and Hypertension
|March 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osteopontin expression in human crescentic glomerulonephritis.

Kidney international·2000
Same author

The diagnostic value of positron emission tomography (PET) with radiolabelled fluorodeoxyglucose (18F-FDG) in head and neck cancer.

The Journal of laryngology and otology·1999
Same author

Clinicopathologic correlations in lupus nephritis in Lima, Peru.

Nephron·1999
Same author

Calreticulin is transported to the surface of NG108-15 cells where it forms surface patches and is partially degraded in an acidic compartment.

Journal of neuroscience research·1999
Same author

KDEL proteins are found on the surface of NG108-15 cells.

Brain research. Molecular brain research·1999
Same author

Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK. HLA Task Force of the Kidney Advisory Group of the United Kingdom Transplant Support Service Authority (UKTSSA)

Lancet (London, England)·1999
Same journal

Primary prevention of chronic kidney disease in type 2 diabetes mellitus with sodium-glucose cotransporter 2 inhibitors.

Current opinion in nephrology and hypertension·2026
Same journal

Financial and policy challenges of delivering kidney replacement therapies in resource-limited settings.

Current opinion in nephrology and hypertension·2026
Same journal

The role of kir4.1/Kir5.1 in mediating the effect of angiotensin-II on Na-Cl-cotransporter.

Current opinion in nephrology and hypertension·2026
Same journal

Role of the calcium-sensing receptor in regulating calcium transport in the thick ascending limb.

Current opinion in nephrology and hypertension·2026
Same journal

Social determinants of chronic kidney disease: from association to clinical and population action.

Current opinion in nephrology and hypertension·2026
Same journal

Advancing science and care in CKD-MBD: the layered path to legacy.

Current opinion in nephrology and hypertension·2026
See all related articles

The complement system plays a key role in kidney health and disease. Inhibiting complement activation can prevent kidney damage and inflammation, offering new therapeutic strategies for renal conditions.

Area of Science:

  • Immunology
  • Nephrology
  • Complement System Biology

Background:

  • The complement system is integral to innate immunity and significantly impacts renal physiology and disease.
  • Deficiencies in complement regulatory proteins or inhibition of complement activation can lead to renal tissue damage.
  • Complement proteins like C5b-9 and CD59 are implicated in glomerular disease progression.

Purpose of the Study:

  • To elucidate the role of the complement system in renal physiology and disease.
  • To explore the impact of complement activation during hemodialysis and xenotransplantation.
  • To identify therapeutic targets for controlling complement-mediated renal injury.

Main Methods:

  • Review of observations linking complement system components to renal pathology.

Related Experiment Videos

  • Analysis of complement activation by cellulosic membranes and its inflammatory mediators (C5a).
  • Evaluation of therapeutic interventions (cobra venom factor, sCR1, anti-C5 monoclonal antibodies) in preclinical models and xenotransplantation.

    • Main Results:

    • Deficiency or inhibition of complement regulatory proteins causes renal damage.
    • Inhibition of complement activation mitigates complement-mediated tissue destruction.
    • Complement activation during hemodialysis produces inflammatory C5a, and its control may impact patient health.
    • Complement activation in xenotransplantation can be managed with agents like sCR1 and anti-C5 monoclonal antibodies.

    Conclusions:

    • The complement system is a critical factor in renal disease pathogenesis.
    • Targeting complement activation presents a promising therapeutic avenue for managing renal conditions.
    • Further research into complement modulation could lead to novel treatments for complex renal diseases.